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Abstract Natural polymers and proteins such as
chitosan (CS) and albumin (Alb) have recently
attracted much attention both in drug delivery and
gene delivery. The underlying rationale is their unique
properties such as biodegradability, biocompatibility
and controlled release. This study aimed to prepare
novel albumin–chitosan–DNA (Alb-CS-DNA) core–
shell nanoparticles as a plasmid delivery system and
find the best conditions for their preparation. Phase
separation method and ionic interaction were used for
preparation of Alb nanoparticles and Alb-CS-DNA
core–shell nanoparticles, respectively. The effects of
three important independent variables (1) CS/Alb
mass ratio, (2) the ratios of moles of the amine groups
of cationic polymers to those of the phosphate groups
of DNA (N/P ratio), and (3) Alb concentration, on the
nanoparticle size and loading efficiency of the plasmid
were investigated and optimized through Box–Behn-
ken design of response surface methodology (RSM).
The optimum conditions were found to be CS/Alb
mass ratio = 3, N/P ratio = 8.24 and Alb concentra-
tion = 0.1 mg/mL. The most critical factors for the
size of nanoparticles and loading efficiency were Alb
concentration and N/P ratio. The optimized nanopar-
ticles had an average size of 176 ± 3.4 nm and
loading efficiency of 80 ± 3.9 %. Cytotoxicity exper-
iments demonstrated that the prepared nanoparticles
were not toxic. The high cellular uptake of nanopar-
ticles (*85 %) was shown by flow cytometry and
fluorescent microscopy.
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Introduction
Attention to gene therapy as a promising therapeutic
approach for the curing of intractable diseases such as
inherited conditions and cancer is increasing rapidly
(Duan et al. 2008; El-Aneed 2004). In addition, gene
therapy can be used as an alternative to conventional
protein therapy when cells lack a crucial protein, since
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it does not have some disadvantages of protein therapy
such as systemic toxicity, high in vivo clearance rate
and high manufacturing cost (Park et al. 2006). The
main purposes of gene therapy are: increasing the
expression of a needed target protein via use of nucleic
acids and decreasing an unwanted target protein
production through use of siRNA and oligonucleotides
(De Laporte et al. 2006). However, the main obstacle
in gene therapy as an effective treatment approach is
the issue of gene delivery, which needs to be resolved
(El-Aneed 2004; Ren et al. 2010). Currently, viral
carriers and non-viral carriers such as peptides, lipids
and dendrimeric or polymeric carriers are the two
main types of carriers that are utilized in gene delivery
(Che et al. 2011; Cryan et al. 2004; Kim et al. 2011b;
Bansal et al. 2010). Although viral delivery has a high
efficiency, its broad use is limited by some disadvan-
tages such as high immunogenicity, limitation in terms
of size of genetic materials delivered and lack of
targeting interaction with certain cells (Duan et al.
2008; El-Aneed 2004; Lee et al. 2011).
One of the most significant non-viral gene delivery
systems is the use of cationic polymers, which have
positively charged groups in their backbone, which
makes it possible to interact with the negative charge
of anionic polymers and genetic materials such as
plasmids and siRNA. CS is among the most significant
cationic polymers that recently have drawn attention
for drug and gene delivery (Mao et al. 2010; Lee et al.
2006).
CS is prepared by the partial N-deacetylation of
chitin and is composed of a (1-4)-2-amino-2-deoxy b-
D-glucan monomers. It is one of the most abundant
modified natural polysaccharides that are commonly
found in crustacean shells, yeast and fungi (Nagpal
et al. 2010). CS is considered as one of the most
promising candidates for gene delivery due to its
desirable properties such as being biocompatible,
biodegradable, non-toxic and inexpensive (Mao et al.
2001; Mansouri et al. 2006; Kim et al. 2011a). Many
reports are already in the literature regarding gene
delivery and drug delivery to cancer cells using CS
nanoparticles (Arya et al. 2011; Kim et al. 2006;
Howard et al. 2006). It is able to form strong
electrostatic interaction with negatively charged
genetic materials via its own cationic amino groups,
which is necessary for protection of nuclease degra-
dation (Mao et al. 2010). In summary, due to its
particular biopharmaceutical characteristics, CS
seems to be among the most suitable carriers in
controlled released systems, protein delivery and gene
delivery.
Protein-based nanoparticles have attracted consid-
erable attention owing to their advantages such as
being non-antigenic, non-toxic, having greater stabil-
ity and the ability to be scaled up during manufacture
(Langer et al. 2003; Rubino et al. 1993; Kommareddy
and Amiji 2005; Azarmi et al. 2006). Albumin (Alb), a
versatile protein carrier for gene delivery and drug
delivery, has some ideal properties for fabrication of
nanoparticles such as being non-immunogenic, non-
toxic, biodegradable and biocompatible (Kratz et al.
1997; Elzoghby et al. 2012). The presence of different
drug binding sites in the Alb molecule makes it
possible that high amounts of drugs can be incorpo-
rated into the Alb nanoparticle matrix (Patil 2003).
Due to the existence of charged amino acids such as
lysine and glutamate in the Alb primary structure, the
electrostatic adsorption of positively and negatively
charged molecules could also be possible (Irache et al.
2005; Weber et al. 2000a). Alb is a soluble and acidic
protein that is stable in wide range of pH (4–9), also
stable at 60 C for 10 h and soluble in 40 % ethanol.
Its preferential accumulation in solid tumor and
inflamed tissues and the above-mentioned properties
make it an ideal carrier candidate for gene and drug
delivery (Kratz 2008).
Several studies have reported preparation of nano-
particles of Alb with positively charged materials such
as poly-L-lysine (PLL), protamine free base and
poly(ethyleneglycol)-modified polyethylenimine
(Singh et al. 2010; Mayer et al. 2005; Zhang et al.
2010). But, to our knowledge, so far nanoparticles
with Alb core and CS shell have not been reported yet.
The CS-Alb core–shell nanoparticles are very suitable
carriers for delivery of genetic materials and drugs or
co-delivery of both of them. Various drugs can be
loaded in the core of this type of nanoparticles;
moreover, genetic materials can be incorporated in
their shells, since DNA can interact with CS via
electrostatic interactions. It was shown that nanomor-
phology could provide significant change in the
properties of semiconductors (Xu et al. 2011; Shao
et al. 2012; Banerjee and Krupanidhi 2010), but here
the main purpose of core–shell structure is to provide
two different parts (core, shell) for loading different
drugs and nucleic acids and further stabilizing of
protein core.
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In the present study, the effects of three key factors
(CS/Alb mass ratio, N/P ratio and Alb concentration)
on the loading efficiency and size of Alb-CS-DNA
nanoparticles containing genetic material were
assessed by response surface methodology. Finally,
cellular uptake and toxicity of the optimized nanopar-
ticles were investigated on the HeLa cell line, which is
the oldest, most widely distributed and permanent
human cancer cell line (Rahbari et al. 2009).
Materials and methods
Materials
Chitosan (CS) (‘‘low MW’’: Cat. No. 448869, Sigma
Aldrich) was used after further purification as will be
described in ‘‘Purification of chitosan’’ Section BSA
(fraction V), glutaraldehyde and all other reagents were
purchased from Merck (Germany); they were of analyt-
ical grade and used as received. The plasmid psiRNA-
hH1GFPzeo was purchased from Invivogen (San Diego,
USA). The EndoFree Plasmid Mega Kit (Cat #12381)
was from Qiagen. FITC-labeled Bcl2 antisense was
purchased from Eurofins MWG Operon (Huntsville,
AL). HeLa cells were from ATCC. Trypsin–EDTA
(T4049), Dulbecco’s modified Eagle’s medium (D6046),
Dulbecco’s phosphate-buffered saline (D8662) and fetal
bovine serum (FBS, F2442) were from Sigma.
Purification of chitosan
CS purification was preformed as described in a
previous study, however with some modifications
(Nasti et al. 2009). Briefly, 3 g of CS was dissolved
in 300 mL of acetic acid solution (2 % w/v) in double-
distilled water and stirred overnight. The solution was
boiled for 15 min to denature and precipitate any
possible protein contaminant, and the resultant mixture
was then centrifuged at 4,500 rpm for 10 min, in order
to separate any aggregated or denatured protein
contaminant. Finally, the supernatant was removed
and passed through 0.4-lm-pore-size filters. CS was
subsequently precipitated from the aqueous phase by
adjusting the pH of the solution to 9 through adding
1 N sodium hydroxide. Following centrifugation, the
precipitate was redispersed in water at pH = 9 and
again sedimented by centrifugation twice. The proce-
dure was repeated with double-distilled water until the
conductivity and pH values became equal with those of
pure water. Finally, the sample was stored at 4 C after
freeze-drying.
Plasmid production
The plasmid psiRNA-hH1GFPzeo (vector for gener-
ating shRNA targeting GL3 luciferase for use in RNAi
experiments) was used as the DNA component for
preparation and optimization of Alb-CS-DNA core–
shell nanoparticles. Following amplification in TOP10
chemically competent Escherichia coli bacteria, it was
purified using the EndoFree Plasmid Mega Kit
(Qiagen). The concentration and purity of purified
plasmid were determined through UV spectrophotom-
etry by measuring absorbance at 260/280 nm.
Nanoparticle preparation
Albumin nanoparticles
Phase separation technique, a technique previously
described by Langer et al. and Weber et al., was used
for preparing Alb nanoparticles (Langer et al. 2003;
Weber et al. 2000b). Briefly, 1 mg/mL of BSA solution
was prepared, and the pH was adjusted to 8.2 with
0.01 M NaOH. The variable amount of BSA stock
solution was added to 10 mL deionized water with pH
8.2 and 10 mM NaCl. 10 mL of ethanol was added with
constant rate (1 mL/min) using a peristaltic pump under
constant stirring (550 rpm) at room temperature. After
10 min to dissolve, 8 % glutaraldehyde solution
(1.175 lL/mg BSA) was added to the reaction in order
to stabilize the nanoparticles. The cross-linking process
was carried out through stirring the reaction overnight.
Later on, a primary centrifugation was performed to
remove the particles that were bigger than 500 nm.
Finally, in order to purify the nanoparticles, secondary
centrifugation (30,000g) and redispersion in deionized
water through ultrasonication were performed two times.
Alb-CS-DNA nanoparticles
Firstly, a suitable amount of DNA (psiRNA-
hH1GFPzeo) and chitosan corresponding to desired
N/P ratio was mixed for 10 min. In preliminary tests,
citrate buffer pH = 5.4, phosphate citrate buffer
pH = 5.4, sodium acetate buffer pH = 5.4 and phos-
phate buffer pH = 5.8 all at 20 mM concentration
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were used. For optimization process, phosphate buffer
was used in order to adjust the pH at 5.8. In addition to
this, suitable amount of prepared Alb nanoparticles
were stirred at 550 rpm. The mixture of CS and DNA
was then added to Alb nanoparticles in a drop-wise
manner. After 30 min, after primary centrifugation,
big aggregates were pelleted and the supernatant was
removed and collected in a new tube. Finally, in order
to purify the nanoparticles and remove the free
polymers, secondary centrifugation (30,000g) and
redispersion in deionized water through ultrasonica-
tion were performed two times. Figure 1 shows the
process of preparing Alb-CS-DNA nanoparticles that
were used for later analysis.
Characterization of particles
The size and zeta potential of Alb-CS-DNA particles
were characterized through photon correlation spec-
troscopy (PCS) using Malvern Zetasizer ZS series and
Scattering Particle Size Analyzer (Malvern Co., UK).
The every run of RSM was measured three times, and
the value was reported as mean ± standard deviation.
Analytical SEM studies of morphological features
were performed for evaluation of shape, size and
aggregation of the nanoparticles. To this end, nano-
particle samples were mounted on metal subs which
were gold-coated under vacuum, and then examined
on a FE-SEM (JSM-6700F; JEOL Ltd., Tokyo, Japan).
FTIR spectra of freeze-dried optimized Alb-CS-
DNA nanoparticles, Alb nanoparticles and purified CS
were measured using Nicolet IR100 FT-IR Spectrom-
eter. The samples were mixed with pure KBr as the
background and compressed into disks using a manual
tablet press.
Loading efficiency and loading capacity
To determine the loading efficiency and loading
capacity, Alb-CS-DNA nanoparticles with different
Fig. 1 Schematic representation of preparation of Alb-CS-DNA nanoparticles
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N/P ratios were centrifuged at 60,000g and 15 C for
60 min and the amount of free plasmid was deter-
mined in supernatant by Nanodrop 2000c spectropho-
tometer (Nano-drop Technologies, Wilmington, DE)
at 260 nm using supernatant of non-loaded nanopar-
ticles as basic correction. The amount of incorporated
plasmid was calculated by the difference between the
initial total amount of plasmid and the measured
amount in the supernatant. The every run of RSM was
measured three times and the value was reported as
mean ± standard deviation. The loading efficiency
and loading capacity of nanoparticles were determined
by using the following equations:
Loading capacity ðLC%Þ ¼ Tplasmid  Fplasmid
Tnanoparticle
 100
ð1Þ
Loading efficiency ðLE%Þ ¼ Tplasmid Fplasmid
Tplasmid
 100
ð2Þ
where Tplasmid, Fplasmid and Tnanoparticle stand for total
amount of plasmid, free amount of plasmid and total
amount of nanoparticle, respectively.
Experimental design
Response surface methodology (Box–Behnken exper-
imental design) was selected to optimize the formu-
lation parameters in preparation of Alb-CS-DNA
nanoparticles for maximum loading efficiency and
minimum diameter. In this study, a 3-factor, 3-level
Box–Behnken experimental design was used to opti-
mize the preparation of nanoparticles with indepen-
dent factors such as CS/Alb mass ratio (X1), N/P ratio
(X2) and Alb concentration (X3) and the three levels
as described in Table 1. Range of independent factors
has been established by previous studies for develop-
ment of CS nanoparticles containing genetic materials
and preliminary experiments (Lavertu et al. 2006).
The Design Expert (STAT-EASE, 7.0.0, Minneap-
olis, MN) software was used for generation and
evaluation of the statistical experimental design. The
design matrix was constructed which included 15
experimental runs. The value of the independent
variables and dependent variables are presented in
Table 2. For regression analysis of the obtained data as
well as estimation of the coefficients in the regression
equation, a statistical program in Design Expert 7.0.0
software was used. The equations were validated by
ANOVA statistical test. In order to determine the
individual and interactive effects of test variables on
the responses, response surfaces were plotted. Addi-
tional confirmation experiments were then performed
so as to verify the validity of the statistical experi-
mental design.
Cytotoxicity of prepared nanoparticles
To investigate the cytotoxicity of prepared nanopar-
ticles, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was used. Mito-
chondrial dehydrogenases of viable cells are able to
cleave the tetrazolium ring of MTT and produce
purple formazan, which is soluble in organic solvent
such as dimethylsulfoxide (DMSO) and insoluble in
water. For performing the MTT assay, HeLa cells
were seeded in each 96-well plate at a density of
1 9 105 cells/mL in 150 lL of DMEM containing
10 % fetal bovine serum, 100 U/mL penicillin and
100 lg/mL streptomycin at 37 C in humidified air
containing 5 % CO2. After overnight incubation, the
medium was replaced with refreshed medium without
FBS and different concentrations of prepared nano-
particles (5–100 lg/mL of nanoparticles) were added.
Control well was without nanoparticles. To provide
statistically reliable results, all specimens as well as
the control were placed in five wells. After 24 h of
incubation of cells with different concentrations of
nanoparticles, cells were washed with PBS and
100 lL MTT solution (0.5 mg/mL in medium) was
added to each well. Following 3 h of incubation at
37 C and 5 % CO2, the MTT solution was removed
carefully and the formed formazan crystals were
dissolved in DMSO. The absorbance was measured at
550 nm in Microplate Reader (Infinite M200, Tecan,
Austria). To determine the relative cell viability, the
following equation was used:
Table 1 Variables used in central composite experimental
design
Independent variables Symbol Levels
-1 0 1
Chitosan/Albumin ratio X1 3 4.5 6
N/P ratio X2 5 10 15
Albumin concentration X3 0.1 0.2 0.3
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Cell viability% ¼ Abs test
Abs Control
 100 ð3Þ
where Abs test and Abs control stand for the absor-
bance value obtained for treated cells with nanopar-
ticles and untreated cells, respectively.
Cell uptake of the nanoparticles
Cellular uptake of prepared nanoparticles were inves-
tigated the HeLa cell line by using the fluorescent
FITC-labeled Bcl-2 antisense embedded in Alb-CS-
DNA nanoparticles, and this process was performed in
a dark setting. The HeLa cells were seeded at
1.2 9 105 cells per well in glass bottom dish, and after
24 h medium from a glass bottom dish was removed
and washed with PBS three times before adding
500 lL of FBS-free RPMI containing Alb-CS-FITC-
Bcl2 antisense nanoparticles to each well with final
concentration of 400 nM. The cells were incubated for
4 h at 37 C and 5 % CO2 at dark. Then, the medium of
each well was removed and washed by PBS. Following
each treatment, the wells were subsequently evaluated
by confocal microscopy (Olympus FV1000-MPE).
For quantitative uptake study, flow cytometry was
used. The HeLa cells were seeded at 1.2 9 105 cells
per well in 24-well plates. To determine the Alb-CS-
DNA uptake, FITC-labeled Bcl-2 antisense was used
and the cells were incubated with labeled Alb-CS-
DNA nanoparticles with final concentration of
400 nM in serum and antibiotics-free medium for
4 h. Treated and untreated cells were washed three
times with phosphate-buffered saline (PBS) and
detached by trypsinization. Then, the pellet of cells
was dispersed in 500 lL PBS. Finally, green emitting
light was measured by FACSCalibur (BD FACSCal-
ibur System) flow cytometry, and results were ana-
lyzed with FlowJo (v.7.6.1).
Results and discussion
Nanoparticle preparation
Since pKa of BSA and CS are around 6.5 and 4.7
(Janes et al. 2001; Ge et al. 1998), CS and Alb have
positive and negative charge, respectively, in tested
pH (5–6), and furthermore, they can interact with each
other through electrostatic interactions. In preliminary
tests, 4 buffers were used for adjusting pH in the range
of 5–6, since only at this range of pH Alb has negative
charge and CS has positive charge. In a previous study,
it was shown that buffer salts can interfere with
preparation of nanoparticles (Langer et al. 2003).
Therefore, it seems necessary that we find best
candidate buffer for nanoparticle preparation. For this
reason, we tested four different buffers. The sizes of
nanoparticles using citrate buffer, phosphate citrate
buffer, sodium acetate buffer and phosphate buffer
were 576 ± 23, 898 ± 32, 403 ± 20 and
291 ± 15 nm, respectively. Among these phosphate
buffers, the one which had smallest most desirable size
was chosen for optimization experiments.
In a previous study, it was shown that the pH value
of the Alb solution had a critical effect on size of Alb
nanoparticles; therefore, pH around 8.2 was selected
for preparation of the core part of Alb-CS-DNA
nanoparticles. To obtain the smallest and most
uniform nanoparticles, based on the previous reports,
the rate of adding ethanol to Alb solution was adjusted
to 1 mg/min (Langer et al. 2003). The size and zeta
potential of Alb nanoparticles were 140 ± 4.1 nm and
-15 ± 3.2, respectively. The zeta potential and size
Table 2 Box–Behnken design matrix (in coded level of three
variables) and response values for nanoparticles size and
loading efficiency
Run Coded variable
levels
Independent variables (response)
X1 X2 X3 Size (nm) Loading
efficiency (%)
1 -1 -1 0 191.3 ± 1.6 80.06 ± 3.2
2 0 -1 -1 176.2 ± 3.8 79.37 ± 1.6
3 0 0 0 189.9 ± 3.1 75.25 ± 2.7
4 -1 0 -1 179.2 ± 1.7 76.88 ± 1.9
5 0 1 -1 182 ± 2.8 66.31 ± 2.9
6 0 0 0 188 ± 4.4 73.19 ± 3.6
7 -1 0 1 202 ± 1.1 72.5 ± 1.7
8 0 -1 1 192.6 ± 1.7 72.56 ± 2.5
9 0 0 0 187.2 ± 3.3 75.22 ± 2.2
10 0 1 1 203.1 ± 1.7 75.25 ± 1.7
11 1 0 -1 176.6 ± 2 64.94 ± 2
12 1 -1 0 195.23 ± 2.2 73.88 ± 2.9
13 1 0 1 186.7 ± 2.2 75.5 ± 2.5
14 -1 1 0 207.3 ± 2.8 73.88 ± 1.4
15 1 1 0 188.4 ± 3.9 70.14 ± 3
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of nanoparticles increased from around -15 mV and
140 nm to more than ?10 mV and 170 nm, after
covering of Alb nanoparticle by CS and formation of
core–shell nanostructure. These results are consistent
with the previous reports where Alb nanoparticles
were coated by cationic polymers such as PLL, PEI
and PEG-PEI, and in their reports, increases in size
and zeta potential have been also observed with
exactly the same trends. The reason for increased size
and zeta potential of nanoparticles has been suggested
to the point that chitosan covered the albumin
nanoparticle through electrostatic interactions, and
core–shell nanostructure was formed (Wang et al.
2008; Singh et al. 2010; Zhang et al. 2010; Zhang et al.
2008).
Zeta potential and polydispersity index
of nanoparticles
For measuring the polydispersity index (PDI) and the
zeta potential of Alb-CS nanoparticles, the zetasizer
was used. As shown in Table 3, the PDI and zeta
potential of nanoparticles ranged from 0.097 to 0.35
and from ?10.4 ± 1.3 to ?19.7 ± 1.4 mV, respec-
tively. The most effective factors on PDI of nanopar-
ticle were Alb concentration and N/P ratio, but they
had opposite trends when we moved from low to high
levels of concentration and N/P ratio, respectively.
The best PDI was obtained when the Alb concentra-
tion was in the lowest level and N/P ratio in the highest
level. The most critical factor on the zeta potential was
the N/P ratio.
Nanoparticles optimization
The response surface methodology (RSM) uses a
combination of mathematical and statistical tech-
niques to design experiments, build models and
evaluate the effects of different parameters. The goal
is to optimize a number of independent variables in
order to achieve the most desired outcome. The
optimization process involves investigating the
response of the statistically designed combinations,
predicting the coefficients by fitting them into a
mathematical model which best fits the experimental
conditions, estimating the response of the fitted model
and checking the adequacy of the model. Central
composite design (CCD) and Box–Behnken design
(BBD) are among the most frequently used RSM
designs and have been widely used in several exper-
iments (Dong et al. 2009). BBD is a spherical and
revolving design, which has been applied in optimi-
zation of chemical and physical processes due to its
logical basis and excellent performance (Muthukumar
et al. 2003; Soto-Cruz et al. 1999).
According to the literature and based on prelimin-
ary experimentation, CS/Alb mass ratio, N/P ratio and
Alb concentration were selected as the independent
variables and the size of nanoparticles and loading
efficiency as the dependent variables. Box–Behnken
design was employed as an experimental design for
the analysis of the interactive effect of these param-
eters and determination of the best conditions for
preparation of Alb-CS-DNA nanoparticles.
As we investigated three important factors, the
design matrix required 15 experiments; the corre-
sponding experimental data are given in Table 2. As
shown in Table 2, the size and loading efficiency of
nanoparticles varied from 176.2 ± 3.8–207.3 ±
2.8 nm and 64.94 ± 2–80.06 ± 3.2 %, respectively.
As shown in Fig. 2, Alb-CS-DNA nanoparticles are
spherical and smooth in shape.
The predicted models were developed applying
multiple regression analysis on the experimental data,
and as a result, following Eqs. 1 and 2 were acquired.
The statistical significance of quadratic models was
Table 3 Polydispersity index, zeta potential and loading
capacity values of prepared CS-Alb-DNA nanoparticles
X1 X2 X3 PDI Zeta potential Loading capacity
1 3 5 0.2 0.163 13.4 ± 1.2 16.75 ± 0.55
2 4.5 5 0.1 0.133 10.4 ± 1.3 17.56 ± 0.29
3 4.5 10 0.2 0.136 15.5 ± 1.3 9.04 ± 0.29
4 3 10 0.1 0.097 17.8 ± 0.9 8.69 ± 0.2
5 4.5 15 0.1 0.089 19.6 ± 1.4 5.6 ± 0.23
6 4.5 10 0.2 0.35 18.8 ± 0.6 8.82 ± 0.39
7 3 10 0.3 0.192 19.1 ± 0.8 8.24 ± 0.17
8 4.5 5 0.3 0.327 14.4 ± 1.1 16.3 ± 0.47
9 4.5 10 0.2 0.14 17.3 ± 1.3 9.04 ± 0.24
10 4.5 15 0.3 0.228 18.6 ± 1.2 6.31 ± 0.13
11 6 10 0.1 0.117 18.5 ± 0.8 8.15 ± 0.23
12 6 5 0.2 0.188 12.2 ± 0.9 17.03 ± 0.55
13 6 10 0.3 0.222 18.1 ± 0.9 9.36 ± 0.28
14 3 15 0.2 0.14 19.7 ± 1.4 5.83 ± 0.1
15 6 15 0.2 0.17 19.5 ± 0.7 6.1 ± 0.24
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studied by using the analysis of variance (ANOVA).
Regression sum of squares (R2) for both models which
were developed for size and loading efficiency were
statistically significant (Table 4).
The statistical significance of the ‘‘size’’ model was
shown by P value of the model, and it was less than
0.05. However, P value of X2X3 in the model was
higher than 0.05, and its removal from the equation
made the model more significant. Therefore, the
following equation was the best equation for predic-
tion of size of Alb-CS-DNA nanoparticles:
Y2 ¼ þ 188:37  4:11X1 þ 3:18X2 þ 8:80X3
 5:71X1X2  3:18X1X3 þ 2:42X21 þ 4:77X22
 4:66X23
ð4Þ
where Y2 represents the size of nanoparticles, and X1,
X2 and X3 represent CS/Alb mass ratio, N/P ratio and
Alb concentration, respectively. The values of R2 and
adjusted R2 for size prediction model were 0.98 and
0.96, respectively. The value of R2 was more signif-
icant, and this indicated that the model was able to
predict nanoparticle size over a specific region of
interest. Moreover, there was a good similarity
between R2 and adjusted R2 which indicated the
adequacy of the model to predict the size of nanopar-
ticle by optimization process. The model’s F-value
and CV were 48.35 and 0.88, respectively. This F
value implied that the model was significant, and there
was very low chance (0.02 %) that an F value as high
as the measured one could occur due to noise. The
small value of CV indicated a good precision and
reliability of the experiments.
In Fig. 3a at fixed Alb concentration of 0.1(mg/mL),
the best particle size was achieved when near to low
level of CS/Alb mass ratio and low level of N/P ratio
were used. In this graph, the biggest nanoparticles were
observed at high level of both CS/Alb mass ratio and
N/P ratio. Figure 3b illustrates the effects of CS/Alb
mass ratio and Alb concentration on the nanoparticle
size when the N/P ratio was fixed at 10. In this
condition, the minimum size of nanoparticles was
maintained at near to middle level of CS/Alb mass ratio
and low level of Alb concentration (0.1 mg/mL).
Based on these data, we can conclude that Alb
concentration had an important role in the size of the
nanoparticles, which might be due to the size of Alb
core that formed in these concentrations. In a previous
study, the effect of Alb concentration on size of Alb
nanoparticles was demonstrated (Langer et al. 2003).
However, CS/Alb mass ratio has less effect on size of
nanoparticles than Alb concentration. In Fig. 3c at
fixed CS/Alb mass ratio at 3, the best results were
obtained with Alb concentration of 0.1(mg/mL) and
lower N/P ratio. The effect of N/P ratio was more
obvious when N/P was equal to or more than 10 and the
size of nanoparticles became prominently enlarged.
The biggest nanoparticles were obtained at Alb
concentration of 0.3 (mg/mL) and N/P ratio of 15.
Loading efficiency is another dependent variable
that was investigated. Maximum and minimum
amounts of loading efficiency were 80.06 ± 3.2 and
64.94 ± 2 %, respectively. P value of the ‘‘loading
efficiency’’ model was lower than 0.05, indicating the
significance of the model. The equation was acquired
for prediction of loading efficiency.
Y2 ¼ þ 74:55  2:36X1  2:54X2 þ 1:04X3
þ 0:61X1X2 þ 3:73X1X3 þ 3:94X2X3
 0:49X21 þ 0:43X22  1:61X23 ð5Þ
where Y2 represents the loading efficiency, and X1, X2
and X3 denote CS/Alb mass ratio, N/P ratio and Alb
concentration, respectively. The values of R2 and
adjusted R2 of the model were 0.9792 and 0.9418,
respectively.
As Fig. 3d demonstrates, at all values of CS/Alb
mass ratio, the maximum loading efficiency was
achieved when N/P ratio of 5 was used. It can also be
appreciated from the graph that the global-maximum
Fig. 2 SEM image of optimized Alb-CS-DNA nanoparticles
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loading efficiency was achieved when N/P ratio and
CS/Alb mass ratio were 3 and 5, respectively. It seems
that at N/P ratio of 5, more plasmid molecules can
interact with CS and at CS/Alb ratio of 3, and most of
CS/plasmid complex can attach to Alb core forming
Alb-CS-DNA/plasmid nanoparticles. It was shown
that complex formation between CS and DNA,
promotes protonation of CS. In addition to this,
additional 17 % of total glucosamine units were
protonated at pH 5.5, following complex formation
between CS and DNA. It may explain the high loading
efficiency at N/P = 5 rather than at a higher N/P ratio.
The same phenomenon has been observed for the
interaction of polycations such as PEI with DNA
(Utsuno and Uludag 2010). Another study reported
the same results for loading efficiency and maximum
loading efficiency was obtained at N/P = 5, although
they attributed it to increased effective surface area for
binding of DNA due to decreased size of nanoparti-
cles (Gazori et al. 2009). In Fig. 3e, at fixed N/P ratio
of 5, the minimum loading efficiency was achieved
when the CS/Alb mass ratio = 3 and Alb concentra-
tion = 0.1 mg/mL were used. Both of these factors
have more effect on loading efficiency, and in case of
both factors, through moving from high level to low
level, increase in loading efficiency was observed.
Figure 3f indicates that maximum loading efficiency
was achieved at N/P ratio = 5 and Alb
concentration = 0.1 mg/mL, when CS/Alb mass ratio
was fixed at 3, while minimum loading efficiency in
this fixed CS/Alb mass ratio was obtained at low level
of Alb concentration and high level of N/P ratio.
However, loading capacity of nanoparticles was not
subject of optimization, the obtained results showed
that loading capacity was affected mostly by N/P ratio
(Table 3) and the highest loading capacity
(17.56 ± 0.29 %) was achieved when low level of
N/P ratio was used.
Optimization
In this study, the goal of optimization was finding the
best conditions that give the maximum loading
efficiency and minimum nanoparticle size. The
regression equation was used for finding the optimal
values of the independent variables. The Design
Expert software was used for solving the regression
equation. The best acquired conditions were at CS/Alb
mass ratio = 3, N/P ratio = 8.24 and Alb concentra-
tion = 0.1 mg/mL; at these values, the minimum
nanoparticle size (176.6 ± 2) and maximum loading
efficiency (80.06 ± 3.2) were achieved. The model
was validated by conducting five experiments in
previously mentioned optimum conditions. Validation
experiments and predicted values for both of the
responses by the related equations were consistent
Table 4 ANOVA results for response surface quadratic model (‘‘size’’ model)
Variables Sum of squares DF Mean square F value p value Prob [ F
Model 1211.51 9 134.61 48.35 0.0002a
X1—chitosan/TPP ratio 135.05 1 135.05 48.51 0.0009
a
X2—pH 81.09 1 81.09 29.13 0.0029
a
X3—N/P ratio 619.52 1 619.52 222.54 0.0001
a
X1 9 X2 130.30 1 130.30 46.81 0.0010
a
X1 9 X3 40.32 1 40.32 14.48 0.0126
a
X2 9 X3 5.52 1 5.52 1.98 0.2180
b
X1
2 21.63 1 21.63 7.77 0.0386a
X2
2 84.03 1 84.03 30.18 0.0027a
X3
2 80.25 1 80.25 28.83 0.0030a
Residual 13.92 5 2.78
Lack of fit 10.07 3 3.36 1.75 0.3844
Pure error 3.85 2 1.92
a Significant (p \ 0.05)
b Not significant (p [ 0.05)
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with each other, so statistical significance of the model
was confirmed by these results. Therefore, the model
has adequate precision for the prediction of nanopar-
ticle size and loading efficiency in the chosen space of
independent variables (in the domain of levels chosen
for the independent variables).
FTIR
The FTIR method was applied to elucidate the
incorporation of CS and Alb in nanoparticles. Figure 4
shows the FTIR spectra of CS, Alb nanoparticles and
Alb-CS-DNA nanoparticles. The FTIR peaks of Alb at
Fig. 3 Response surface plots (a, b, c, d, e and f) showing the effect of CS/Alb mass ratio, N/P ratio and albumin concentration on the
nanoparticles size and loading efficiency
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1,532, 1,642, 2,928 and 3,427 cm-1 (curve b) are
assigned to amide II (the coupling of bending vibrate
of N–H and stretching vibrate of C–N), amide I
(mainly C = O stretching vibrations), amide A
(mainly—NH stretching vibration) and the stretching
vibration of –OH bands, respectively (Huang et al.
2010). The peaks of C–O stretching vibration in
chitosan appeared at 1,029 and 1,079 cm-1 (curve a).
The peaks of CS at 1,581, 1,795 and 3,427 cm-1
(curve a) are assigned to amide III, I and symmetric
vibration of NH, respectively (De Souza Costa-Junior
et al. 2009). Hydrogen bonding between OH of CS and
OH of Alb results in shifting of 3,427 cm-1 (curve a)
to 3,414 cm-1, which is the peak. NH3
? peak of CS
and Alb appeared at 1,581 and 1,642, respectively,
NH3
? interaction of CS and BSA made a shift from
1,642 to 1,653, and Alb NH3
? peak became stronger.
Our finding is validated by the previously reported
research (Xu et al. 2012).
Cytotoxicity studies
MTT assay was used for evaluation of cellular toxicity
of Alb-CS-DNA nanoparticle on HeLa cells. The
result is shown on Fig. 5. Cell toxicity was not
observed at 10 lg/mL concentration of Alb-CS-DNA
nanoparticles, which indicates that the cell viability is
near 100 % at this concentration. At high concentra-
tions of Alb-CS-DNA nanoparticles, cell viability was
around 85 %; however, we should note that these
higher concentrations are about ten times more than
the necessary concentration of Alb-CS-DNA
nanoparticles used on the transfection assays for gene
delivery. An interesting observation was that when the
cell viability of Alb-CS-DNA nanoparticles was
compared with CS, the toxicity of CS was a little
more than Alb-CS-DNA nanoparticles, while in case
of Alb, the cell viability was more than 100 %. This
phenomenon can be explained by a nutrient effect
(Fischer et al. 2003). This may suggest that the
existence of Alb could promote biocompatibility of
Alb-CS-DNA nanoparticles.
Fig. 4 FTIR of purified CS (a) and Alb nanoparticles (b) and
Alb-CS-DNA nanoparticles (c)
Fig. 5 MTT assay for different concentrations of the optimized
Alb-CS-DNA nanoparticles, CS and Alb
Fig. 6 Cellular uptake of Alb-CS nanoparticles, HeLa cells
treated with nanoparticles for 4 h and the uptake assessed by
flow cytometry
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These results demonstrate that the prepared Alb-
CS-DNA nanoparticles are non-toxic and have good
biocompatibility in the selected experimental condi-
tions. In addition, our data are also consistent with the
previous studies, which have indicated that Alb
nanoparticles and Alb nanoparticles coated with PLL
and PEI were non-toxic (Wang et al. 2008).
Investigation of cellular uptake by flow cytometry
and confocal microscopy
As Alb-CS-DNA nanoparticles contained the FITC
dye, the degree of Alb-CS-DNA nanoparticles uptake
was quantified with flow cytometry by determining the
green fluorescence emitted from Alb-CS-DNA treated
cells. The cells with green fluorescence intensity
higher than 101 were taken as cells containing Alb-CS-
DNA nanoparticles by setting the logarithmic fluores-
cence intensity of untreated cells between 100 and 101.
Flow cytometry results demonstrated that more
than 85 % of HeLa cells had nanoparticle uptake
(Fig. 6); hence, the Alb-CS-DNA nanoparticles seem
to have good ability for penetrating the cells. For
further investigation about the Alb-CS-DNA nano-
particles uptake, confocal microscopy was used. In
Fig. 7, the presence of nanoparticles inside the cells
was demonstrated, and the image demonstrates that
they tend to collect around the nucleus. According to
both flow cytometry and confocal microscopy, we can
conclude that Alb-CS-DNA nanoparticles have high
levels of uptake by the cells (Figs. 6 and 7).
Conclusion
Plasmid-loaded Alb-CS-DNA core–shell nanoparti-
cles were successfully prepared by ionic interaction
between opposite charges. Box–Behnken design was
used for investigating the effect of three important
independent variables (CS/Alb mass ratio, N/P ratio
and Alb concentration) on the two dependent vari-
ables, that is, loading efficiency and nanoparticle size
for optimization of the plasmid-loaded Alb-CS-DNA
core–shell nanoparticle. Under the optimal conditions
for maximizing the loading efficiency and minimizing
nanoparticle size (CS/Alb mass ratio = 3, N/P
ratio = 8.24 and Alb concentration = 0.1 mg/mL),
the loading efficiency and nanoparticle size were
176.2 ± 3.8 nm and 80.06 ± 3.2 %, respectively,
and the model validation was performed by the
experimental results. Cytotoxicity tests showed that
the optimized nanoparticles have little toxicity and
good biocompatibility. High cellular uptake of opti-
mized Alb-CS-DNA nanoparticles was demonstrated
by ex vivo cellular uptake (*85 %) studies on HeLa
cell line. In comparison with other nanoparticles, this
core–shell nanoparticle provides two separate parts for
delivery of different drugs and nucleic acids, and in
comparison with PLL and PEI, chitosan is more
biocompatible and less toxic, which in turn suggests
that core–shell nanoparticle (Alb as a core and CS as a
shell) would be more biocompatible. Based on the
results of our study, we have concluded that the novel
Alb-CS-DNA core–shell nanoparticles can be consid-
ered as a potential carrier for gene and drug delivery.
Fig. 7 Cellular uptake study of FITC-labeled Alb-CS-DNA nanoparticles after 4 h of incubation a. Nucleus of cells has been identified
through Hoechst staining b. Fluorescent image of HeLa cells c. (a) and (b) merged
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